The role of BRAF mutations in NSCLC and the potential treatment with BRAF and MEK inhibitors.

Dr. Mark Kris, MD or Memorial Sloan Kettering discuss the role of BRAF mutations in NSCLC and the potential treatment with BRAF and MEK inhibitors.